Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Supernus Pharmaceuticals, Inc. (SUPN) had Normalized Pre-Tax Income of $-1.91M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$211.57M |
|
$-4.11M |
|
$23.01M |
|
$188.56M |
|
$215.51M |
|
$-3.94M |
|
$2.02M |
|
$-1.91M |
|
|
Normalized Pre-Tax Income |
$-1.91M |
$-4.11M |
|
$-4.11M |
|
$-4.11M |
|
$-4.11M |
|
$-3.94M |
|
-- |
|
57.34M |
|
57.34M |
|
$-0.07 |
|
$-0.07 |
|
| Balance Sheet Financials | |
$644.18M |
|
$10.53M |
|
$808.47M |
|
$1.45B |
|
$338.17M |
|
-- |
|
$52.76M |
|
$390.93M |
|
$1.06B |
|
$367.38M |
|
$1.06B |
|
57.46M |
|
| Cash Flow Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|